The invention relates to a novel crystalline form of nelfinavir mesylate and processes for its preparation. More particularly, it relates to the preparation of crystalline form of nelfinavir mesylate designated as Form I. The invention also relates to pharmaceutical compositions that include the crystalline Form I of nelfinavir mesylate and use of said compositions for treatment of HTV-I infections. The invention also relates to a process for the preparation of nelfinavir or a salt thereof.
